Actinium Pharmaceuticals (NYSE:ATNM) Shares Up 2.9%

Actinium Pharmaceuticals, Inc. (NYSE:ATNMGet Rating) shares shot up 2.9% during trading on Friday . The stock traded as high as $5.74 and last traded at $5.73. 103,414 shares changed hands during mid-day trading, a decline of 76% from the average session volume of 438,423 shares. The stock had previously closed at $5.57.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 3rd.

Actinium Pharmaceuticals Price Performance

The business’s fifty day moving average price is $5.11.

Actinium Pharmaceuticals (NYSE:ATNMGet Rating) last posted its quarterly earnings results on Friday, May 13th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.08. The company had revenue of $0.94 million during the quarter. Actinium Pharmaceuticals had a negative return on equity of 32.44% and a negative net margin of 1,681.46%. On average, analysts forecast that Actinium Pharmaceuticals, Inc. will post -1.07 earnings per share for the current year.

Actinium Pharmaceuticals Company Profile

(Get Rating)

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.

Recommended Stories

Want More Great Investing Ideas?

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.